Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + VRd in Untreated Multiple Myeloma
NCT03652064Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Overall Minimal Residual Disease Negative Rate at 27.9 months and Final Progression-Free Survival Analysis: Overall Minimal Residual Disease Negative Rate at 64.8 months. Started Nov 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03652064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652064.